Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...